Dokumentdetails
ID
oai:HAL:hal-03851647v1
Thema
glyco-engineering glycosides influenza viruses sialosides solid lipid microparticles [SDV.BIO]Life Sciences [q-bio]/Bio... [SDV.MHEP.MI]Life Sciences [q-bio]...Autor
Richard, Emeline Traversier, Aurélien Julien, Thomas Rosa-Calatrava, Manuel Putaux, Jean-Luc Jeacomine, Isabelle Samain, EricLangue
enEditor
HAL CCSD;Oxford University Press (OUP)
Kategorie
CNRS - Centre national de la recherche scientifique
Jahr
2022
Auflistungsdatum
07.10.2023
Schlüsselwörter
solid lipid microparticles production sslms influenza virus sialylatedZusammenfassung
International audience; Abstract Influenza viruses bind to their target through a multivalent interaction of their hemagglutinins (HAs) with sialosides at the host cell surface.
To fight the virus, one therapeutic approach consists in developing sialylated multivalent structures that can saturate the virus HAs and prevent the binding to host cells.
We describe herein the biotechnological production of sialylated solid lipid microparticles (SSLMs) in 3 steps: (i) a microbiological step leading to the large-scale production of sialylated maltodextrins by metabolic engineering of an Escherichia coli strain, (ii) a new in vitro glycosylation process using the amylomaltase MalQ, based on the transglycosylation of the terminal sialoside ligand of the sialylated maltodextrin onto a long-chain alkyl glucoside, and (iii) the formulation of the final SSLMs presenting a multivalent sialic acid.
We also describe the morphology and structure of the SSLMs and demonstrate their very promising properties as influenza virus inhibitors using hemagglutination inhibition and microneutralization assays on the human A/H1N1 pdm09 virus.
Richard, Emeline,Traversier, Aurélien,Julien, Thomas,Rosa-Calatrava, Manuel,Putaux, Jean-Luc,Jeacomine, Isabelle,Samain, Eric, 2022, Biotechnological production of sialylated solid lipid microparticles as inhibitors of influenza A virus infection, HAL CCSD;Oxford University Press (OUP)
